The Value of Inflammatory Prognostic Index in Older Patients With Hormone Receptor Positive Metastatic Breast Cancer

Abstract

Objectives: To search the prognostic value of an inflammation based prognostic score in older patients with hormone positive, Her2 negative metastatic breast cancer. Methods: A retrospective study of 82 female patients aged 65 years and older with hormon receptor positive, Her-2 negative metastatic breast cancer diagnosed between 2011 and 2018 was conducted with collection of clinical and laboratory data. The inflammatory prognostic index (IPI) was calculated as C-reactive protein × NLR (neutrophil/ lym- phocyte ratio)/serum albumin. Survival estimates were calculated with Kaplan-Meier method. Results: The optimal cut-off points of IPI for the stratification of OS was found to be 0,75. Based on this cutoff value, patients were categorized as IPI-high and IPI-low group. High IPI was significantly associated with advanced stage at diagnosis. (p=0.03) The mean OS was 64 months in the IPI-high group and 66.9 months in the IPI-low group. (p=0,813) In patients receiving hormonotherapy in first line treatment PFS was 34.6 months in the IPI-low group and 14.5 months in the IPI high group, and a statistically significant difference was found compared to patients who received chemo- therapy in the first line. (p=0,042). Conclusion: Measurement of systemic inflammatory response in older adults with metastatic breast cancer is reliable, available, and can be clinically incorporated into current geriatric oncology algorithms